Supplementary Figure 1.png (301.61 kB)

Supplementary Figure 1. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

figure

posted on 2021-10-15, 15:08 authored by Saaya Tsutsué, Takahiro Suzuki, Hyojin Kim, Bruce Crawford

Supplementary Figure 1. Patient survival (A) overall (B) by age-group (C) by 1L. Patients were categorized by treatment regimen received in the 1L of therapy. AZA, azacitidine; ESA, erythropoiesis-stimulating agents.

Funding

Bristol-Myers Squibb

History

Usage metrics

Read the peer-reviewed publication

Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

Future Oncology

Keywords

Myelodysplastic Syndromes Treatment Cost Health Care Economics Japan Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0